搜索
··〔2016〕86《·》、《·》。。753－2510080020378863263788632137886330gdsyxh45@126．comhttp//．sinopharmacy．com．cn《·》201684·2016201684、。、。。、、。、、、。。、、。73、、。“”、“”。2016630·906·20169269PharmacyToday2016SepVol．26No．9、GCPSOP。。。、adverseeventAE。。1．1－3。3“”“”ad-versedrugreactionADＲ。、、、。2．3-5seriousadverseeventSAE“”。。。、。。。。。、。。3．13-4severeserious。、。“severe”。“serious”6。“”。4．、46-7、SuspectedUn-expectedSeriousAdverseＲeactionSUSAＲ、。、。。。、/、、、、·016·PharmacyToday2016SepVol．26No．920169269。1．28-9。。。/。/。、/。“”12“”。、、。、。2．2468。。“”“”。“”。。3．10-11、。。SOP。4．26、、、。。5．212///。1。CDISCtheClinicalDataInterchangeStandardsConsortiumCDASHClinicalDataAcquisitionStandardsHarmonization“”“”。。“”。。“”“”“”“/”。。“”。2“/”。6．813、、、/“”。7．/214-156、、、、·116·20169269PharmacyToday2016SepVol．26No．9、。、、、、、《》。8．216。。。9．317WHO、NCICTCAE。、、NCICTC1～5。。Ⅱ35～310I35～36Ⅱ37～38I39～310。。、/2-31118-19。、。1．、/、/2．KarchLasagna、Naranjo。CFDA“”1。1CFDA++++－++++－++±±－+－、++－±－+－±。3．5“”“”“”“”。4．“”。5．、、、、、、。、、、、。、。。·216·PharmacyToday2016SepVol．26No．920169269、181．、《》。、CＲF。CＲF。、、、。。、、SOP。2．GCP2420。。。SOP、GCP。。3．“”。4。、//。/。、、、、。1．/111//。21。14。“”。、、、。。、。2．/1214/2。2/、282862828、1．21-22。·316·20169269PharmacyToday2016SepVol．26No．9“”“”。“”、/、、、。CSclinicalsignificance“”NCSnon-clinicalsignificance“”。。2．/4、/。。1/、。2、3。。4、。5、。6。7/。。84、、。IＲB。3．1-31ICH。、2243。。·416·PharmacyToday2016SepVol．26No．920169269。、、、、。3。3、、、、～、CＲF～、。、1ICHE6Ｒ1ICHharmonizedtripartiteguideline．GuidelineforGoodClinicalPracticeEB/OL．http//．gbv．de/dms/bs/toc/350771871．pdf1996-06-10/2016-07-20．2Merck＆Co．Inc．AdverseEventＲeportFormandGuidelinesForNon－seriousandSeriousAdverseEventsＲelatedtoＲaltegra-virinIMPAACTP1097EB/OL．http//impaactnetwork．org/DocFiles/P1097/P1097AEＲeportingMerckInstructions05May11．pdf2016-07-20．3NormanM．Goldfarb．AdverseEventTerminologyJ．JournalofclinicalresearchBestpractices201287．4ICHE2AsectionⅡandEdwardsI．Ｒ．etalHarmonizationinPharmacovigilanceJ．DrugSafety199410293-102．5CIOMSV/VIＲeportCurrentChallengesinPharmacovigilancePragmaticApproachesCurrentChallengesinPharmacovigi-lancePragmaticApproachesM．TheCIOMSVWorkingGroupWG2009297-298．6MichaelJ．KlepperBrianEdwards．IndividualCaseSafetyＲe-portsHowtoDeterminetheOnsetDateofanAdverseＲeac-tionJ．DrugSafety2011344299-305．7EuropeanCommissionEnterpriseDirectorate-GeneralDetailedguidanceontheEuropeandatabaseofSuspectedUnexpectedSeriousAdverseＲeactionsEB/OL．http//ec．europa．eu/health/files/pharmacos/docs/doc2003/april/cp-guidance-eud-ravigilance_160403_en．pdf2003-04/2016-07-15．8S．EricCeh．AdverseEventＲeportingDuringtheStudyJ．JournalofclinicalresearchBestpractices200958．9CIOMSV/VIGuidelinesforPreparingCoreClinical-SafetyIn-formationonDrugsM．TheCIOMSVWorkingGroupWGSecondEdition1999Chapter36．10ICTDＲInvestigatormanualmonitoringandreportingadversee-ventsEB/OL．http//．icssc．org/Documents/Ｒesources/ICTDＲ_AE_Manual_February_6_2003_final．pdf．2003－02-06/2016-07-19．11H/EPDF．GeneralconsiderationsforclinicaltrialsM．ICHE8200511-2．12CDISCTheClinicalDataInterchangeStandardsConsortium．EB/OL．http//imaging．cancer．gov/programsandre-sources/reportsandpublications/CDISC2004-06-25/2016-07-21．13FDAGuidanceGoodPharmacovigilancePracticesandPhar-macoepidemiologicAssessmentEB/OL．http//．fda．gov/downloads/ＲegulatoryInformation/Guidances/UCM126834．pdf2005-03/2016-07-21．14GuidanceonＲeviewingandＲeportingUnanticipatedProblemsInvolvingＲiskstoSubjectsorOthersandAdverseEventsM．U．S．departmentofHealth＆HumanServices2010．15FDAGuidanceGuidanceforIndustryPostmarketingAdverseEventＲeportingforNonprescriptionHumanDrugProductsMarketedWithoutanApprovedApplicationEB/OL．http//．fda．gov/Down-loads/Drugs/GuidanceComplianceＲegu-latoryInformation/Guidances/UCM171672．pdf2012-06-30/2016-07-21．16FDAGuidanceGuidanceforIndustryandInvestigatorsSafetyＲeportingＲequirementsforINDsandBA/BEStudiesEB/OL．http//．fda．gov/downloads/drugs/guidancecompli-anceregulatoryinformation/guidances/ucm227351．pdf2012-12/2016-07-21．17GayHADykPDeasyJOetal．CommonTerminologyCrite-riaforAdverseEventsCTCAEv4．0BasedHybridPatientandPhysicianQuestionnaireforHeadandNeckHNＲadio-therapySymptomＲeportingJ．Fuel＆EnergyAbstracts2011812S673．18．《》81EB/OL．http//．sda．gov．cn/WS01/CL0053/62621．html2011-05-04．19Cobert．BL．Cobert＇smanualofdrugsafetyandpharmacovigi-lance/M．Jones＆BartlettLearning2010．20．《》3EB/OL．http//．sda．gov．cn/WS01/CL0053/24473．html2003-08-06．21DocumentingClinicallySignificantLabValuesJ．JournalofclinicalresearchBestpractices2009511-4．22NationalMarrowDonorProgramEventＲeportingTerminologyQuickＲeferenceEB/OL．https//．cibmtr．org/DataMan-agement/Documents/Event%20Ｒeporting%20Terminology%20Quick%20Ｒeference．pdf2016-07-20．23FDAGuidanceforIndustry．EstablishingPregnancyExposureＲegistriesEB/OL．http//．fda．gov/cder/guidance/3626fnl．pdf．2012－08/2016-07-20．·516·20169269PharmacyToday2016SepVol．26No．9